ARIAD ANNOUNCES SUPPORT OF PATIENTS WITH RESISTANT OR INTOLERANT CML THROUGH ITS DONATION TO CHRONIC DISEASE FUND

April 2, 2013

Cambridge, MA, April 2, 2013 –- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it had made a donation to the Chronic Disease Fund (CDF) in support of patients with chronic myeloid leukemia (CML) who are resistant or intolerant to prior therapy. CDF is an independent non-profit charitable organization that helps eligible patients with chronic diseases, cancer and other life-altering conditions obtain the life-saving medications they need. Through ARIAD’s contribution, the organization will provide financial assistance to eligible patients with resistant or intolerant CML who require help paying their out-of-pocket expenses, including co-pays or co-insurance. CDF will determine the distribution of these funds and patient eligibility.

“Approximately 5,000 new cases of CML are diagnosed each year in the United States, and over time, many of these patients will develop resistance or intolerance to tyrosine kinase inhibitors,” said Marty Duvall, senior vice president, commercial operations at ARIAD.  “ARIAD is dedicated to helping these refractory or intolerant patients receive the medications they need, and we are proud to support the CDF as it assists patients.”

In addition, ARIAD has a patient assistance and support program designed to help healthcare professionals or patients access, afford and adhere to treatment. Information on the ARIAD PASS™ program for patient assistance is available by calling 1-855-447-PASS (855-447-7277) or visiting www.ARIADPASS.com.

 

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines.  ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers.  ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.  For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).  

 

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.